Cytotoxic activity of invariant NKT cells in human allergic contact dermatitis by Balato, Anna
 1 
Università degli Studi di Napoli Federico II 
Facoltà di Medicina e Chirurgia 
 
 
 
 
Tesi di Dottorato di Ricerca  
in 
Fisiopatologia Clinica e Medicina Sperimentale 
(Coordinatore: Prof. G. Marone) 
XXII Ciclo 
2006-2009 
 
Cytotoxic activity of invariant NKT cells in human allergic contact dermatitis 
 
 
 
 
 
Tutor               Candidata  
Prof. Fabio Ayala      Dott.ssa Anna Balato 
 
 
 
 
 2 
Index 
Introduction……………………………………………………………………….pag. 4 
Regulatory role of NKT cells……………………………………………pag. 8 
Ligands……………………………………………………………………pag. 9 
Functional subsets of NKT cells………………………………………..pag. 13 
Antigen presentation and activation of NKT cells by non-professional 
APCs………………………………………………………………………pag. 21 
NKT and cytotoxicity……………………………………... ……………..pag. 23 
Table 1…………………………………………………………………….pag. 26 
Figure 1…………………………………………………………………...pag. 27 
Materials and methods………………………………………………................pag. 28 
 Human subjects………………………………………………………….pag. 27 
 RNA extraction, cDNA synthesis, and real-time PCR……………….pag. 28 
 Reagents and antibodies……………………………………………….pag. 29 
 Immunohistochemical procedures…………………………………….pag. 30 
 Primary KC, HaCaT, THP-1 and K562 cell lines…………………….pag. 30 
 NKT-cell assay…………………………………………………………..pag. 31 
 Cytotoxic assays………………………………………………………...pag. 31 
 Statistical analyses……………………………………………………...pag. 32 
 Table 2……………………………………………………………………pag. 33 
Results……………………………………………………………………….…..pag. 34 
 Cytotoxic molecules gene expression in ACD……………………….pag. 34 
 Co-localization of NKT cells and cytotoxic molecules in ACD……..pag. 35 
 3 
 Gene expression during antigen presentation………………………pag. 36 
 NKT cell cyototoxic activity vs keratinocytes………………………...pag. 37 
Discussion……………………………………………………………………….pag. 38 
References………………………………………………………………………pag. 42 
 4 
 Introduction 
Natural killer T cells (NKT cells) are a unique subset of T-lymphocytes that 
express a T-cell receptor (TCR) a/ß, with a restricted repertoire (Godfrey et al., 
2004). This distinguishes them from NK cells, although NKT cells share some 
markers characteristic of NK cells such as CD161 (CD161c is known as NK1.1 in 
mice) or NKR-P1 (Godfrey et al., 2004). In contrast to conventional T-
lymphocytes and other Tregs, the NKT cell TCR does not interact with peptide 
antigen presented by classical major histocompatibility complex (MHC)-encoded 
class I or II molecules, but instead it recognizes glycolipids presented by CD1d, a 
nonclassical antigen–presenting molecule that associates with ß2 microglobulin  
(Godfrey et al., 2000 and Kronenberg et al., 2002).  
Polymorphic MHC molecules present peptide antigens that are specifically co-
recognized by aß TCRs expressed on T-cells. These TCRs are highly specific 
and restricted to recognizing the MHC molecules of the individual from which 
they were derived; this concept is known as MHC-restriction.  
In contrast, CD1 family members are monomorphic MHC class-I-like 
glycoproteins that present lipid-based antigens recognized by T-cells, even 
across species. The antigen-binding cleft of the CD1 family contains large 
hydrophobic pockets that are ideally suited to binding lipid antigens and, on the 
basis of sequence identity and chromosomal location, are divided into CD1a, 
CD1b, CD1c, CD1d and CD1e family members. Although humans express all 
family members, only the CD1d genes are present and expressed in mice and 
rats. CD1a, b and c are most homologous to each other and are expressed by 
thymocytes, dendritic cells and activated monocytes, (Dougan et al., 2007) while 
 5 
B cells express only CD1c, among these 3 family members (Small et al., 1987). 
CD1d is divergent in sequence from CD1a, b and c (Balk et al., 1989) and its 
tissue distribution is more widespread, including cells outside the lymphoid and 
myeloid lineages (Canchis et al., 1993; Exley et al., 2000). In addition CD1d is 
expressed in epidermal keratinocytes (KCs) in the skin, and by several other 
peripheral epithelia or stromal cells in diverse organs such as the intestine, liver, 
kidney, pancreas, uterus, and conjunctiva (Sieling, 2000). Some bone marrow-
derived cells, such as B cells and monocyte-derived dendritic cells, also express 
CD1d (Sieling, 2000). Thus, the wide distribution of CD1d in widely divergent 
tissues by predominantly nonprofessional antigen presenting cells (APCs) 
suggests that it plays an important, yet poorly defined, role in both health and 
disease states (Fishelevich et al., 2006). CD1a, b and c molecules, which can 
present self and foreign (microbial) lipid antigens, are generally recognized by 
polyclonal T-cells expressing aß TCRs or by some ?d T cells that recognize 
CD1c. The recognition of glycolipid antigens in association with CD1d means that 
NKT cells recognize a class of antigens ignored by conventional T-cells. 
Relatively few examples of these antigens are defined, although presentation of 
several mycobacterial cell wall antigens by the 3 other human CD1 molecules, 
CD1a, CD1b and CD1c, has been well characterized (Gumperz et al., 2001), as 
has presentation of several autologous antigens, including gangliosides and 
some phospholipids. The compound most efficient for activating the majority of 
NKT cells is a synthetic glycolipid (originally derived from a marine sponge) 
known as a-galactosylceramide (aGalCer) (Hayakawa et al., 2004 and Hong et 
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al., 1999). This compound binds effectively to CD1d, and the complex of 
glycolipid plus CD1d binds the NKT cell TCR (Sidobre et al., 2002). aGalCer is 
widely used as a highly specific antigen for both human and murine NKT cells. In 
both species, these cells use precisely rearranged homologous TCR variable 
(V)a and junctional (J)a segments.  
In mice, NKT cells most express an invariant TCR a chain rearrangement (Va14-
Ja18) with a conserved CDR3 region, and they typically coexpress either Vß8.2, 
Vß2, or Vß7. Similar T-cells are present in other mammalian species, including 
humans. The homologous population of human invariant NKT cells express a 
Va24-Ja18 rearranged TCR a chain with a Vß11-containing ß chain (Dellabona 
et al., 1994 and Porcelli et al., 1993). The evolutionary conservation of these 
cells is striking, as mouse NKT cells recognize human CD1d plus glycolipid 
antigen and vice versa (Brossay et al., 1998).  
NKT cells may be double negative for CD4/CD8 or may be single positive for 
CD4 or CD8. During development in the thymus, rare CD4+ CD8+ (DP) cortical 
thymocytes that successfully rearrange the semi-invariant TCR are directed to 
the Va14 NKT cell lineage via interactions with CD1d-associated endogenous 
glycolipids expressed by other DP thymocytes. As they mature, Va14 NKT 
lineage cells upregulate activation markers such as CD44 and subsequently 
express NK-related molecules such as NK1.1 and members of the Ly-49 
inhibitory receptor family (MacDonald HR et al., 2007).  
The distribution of NKT cells and NK cells is different; NKT cells are found  
everywhere that conventional T-cells are found. In mice, NKT cells represent 
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approximately 30% of the total lymphocytes in the liver (50%of aßTCR+ T cells), 
20% of the aß T-cells in the bone marrow, and 3% of the aßT cells in the spleen, 
but are rare in the lymph node (Berzins et al., 2004; Emoto & Kaufmann, 2003; 
Godfrey et al., 2000). In humans, only 0.2% of peripheral blood T-cells are NKT 
cells. They are also present in the human liver but their numbers are lower than 
in the liver of mice (Prussin & Foster, 1997; Benlagha et al., 2000; Norris et al., 
1999). NKT cells predominate in the liver, while conventional T cells prevail in 
blood and lymph node. In contrast, the order for NK cell frequency is lung > liver 
> peripheral blood mononuclear cells (PBMCs) > spleen > bone marrow > lymph 
node > thymus, where NK cells are almost undetectable (Gregoire et al., 2007).  
NK cells are lymphocytes that play a vital role in cell-mediated immunity, and 
serve as the first line of defense against cancerous and virally infected cells. 
Their cytolytic activity is not regulated by antigenic specificity, but through a 
balance of activating or inhibitory signa ls mediated through cell surface 
receptors. These receptors specifically bind human leukocyte antigen (HLA) 
ligands (Bashirova et al., 2006), which are expressed in virtually all nucleated 
cells but downregulated in aberrant cells, thus allowing NK cell reconnaissance. 
This mode of recognition was first referred to as the ‘missing self’ hypothesis 
(Ljunggren et al., 1990). 
Although most NKT cells express NK cell markers such as CD161, they also 
contain a small population of cells that are negative for NK cell markers (Godfrey 
et al., 2004). Importantly, CD1d-restricted T cells also contain T-cells that neither 
express the canonical TCR a-chain nor respond to aGalCer (Duarte et al., 2004 
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and Terabe et al., 2005). To avoid confusion, it has recently been recommended 
that NKT cells should be defined by their reactivity to aGalCer loaded onto CD1d 
multimers, instead of expression of NK cell markers (Godfrey et al., 2004). It is 
apparent, now, that the simple classification of NKT cells as T-lymphocytes that 
also express NK receptors is inadequate.  
Robson MacDonald reviewed the discovery of NKT cells through time. Early in 
the history, there was no connection with the NK cell lineage for either Vß8-
biased DN thymocytes or Va14-expressing peripheral T-cells. He reported that 
this could probably be traced to the fact that only T-cell biologists were studying 
these rare populations and there was no reason at the time to suspect any 
shared markers between T and NK cells. On the other hand, NK cell biologists 
often were required to exclude T-cell markers from their analysis, putting them in 
a better position to identify shared phenotypic properties (Robson MacDonald, 
2007). Around 1990, it was recognized that a subset of lymphocytes in spleen 
and bone marrow shared NK and T-cell markers (Yankelevich et al., 1989; 
Sykes, 1990). Importantly, this was also shown to be true for the DN Vß8-biased 
thymocyte subset (Ballas & Rasmussen, 1990). At this point in time “NKT” cells 
finally had a birth certificate but still were not linked to expression of the Va14 
chain. 
 
Regulatory role of NKT cells 
NKT cells influence and regulate a wide range of immune responses. They share 
some characteristics with CD25+CD4+ Tregs, which, also regulate different types 
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of immune responses and which also have recently attracted much attention 
(Godfrey and Kronenberg, 2004). 
CD4+CD25+ Tregs are essential for the control of immune responses in 
inflammatory, autoimmune, or cancer diseases, and it is well established that in 
particular the lineage-specific transcription factor Foxp3, as well as cytokines 
(including IL-2, IL-10, and TGF-ß), characteristic surface markers such as CTLA-
4, and members of the TNF superfamily (e.g., RANKL) are critically involved in 
the thymic development, peripheral maintenance, and suppressive activity of 
CD4+CD25+ Tregs (Kim, 2007). 
There are some clear similarities between NKT cells and CD4+CD25+ Tregs, 
including expression of CD25 by human CD4+ NKT cells (Lee et al., 2002). This 
raises the possibility of confusion between these distinct types, such that some 
activity ascribed to CD25+CD4+ Tregs might really be due to NKT cells. It is 
therefore important to carefully distinguish these cells (Godfrey and Kronenberg, 
2004). In Table1 similarities and differences among NKT cells, NK cells, T cells 
and CD25+CD4+ Tregs are summarized. 
 
Ligands 
Since aGalCer, was discovered as a potent ligand for NKT cells (Kawano et al., 
1997), a synthetic aGalCer has widely been used for study of NKT cells as a 
surrogate ligand. It is now established that two lipid chains of aGalCer are 
inserted to hydrophobic grooves of the CD1d glycoprotein expressed by APCs 
(McCarthy et al., 2007), whereas the a-linked sugar moiety is accessible and 
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recognized by the TCR of NKT cells. Recently, the crystal structure of the 
invariant TCR and CD1d loaded with aGalCer has shown a very unique 
orientation of TCR towards CD1d (Borg et al., 2007), which allows a selective 
involvement of the invariant a-chain for recognition of the a-linked sugar. 
Comparison of aGalCer with its structurally altered analogues has provided 
important insights into how NKT cells may differentially respond to 
glycosphoingolipids with lipid tail variants (Brutkiewicz, 2006; Miyake & 
Yamamura, 2007). An aGalCer analogue called OCH (Miyamoto et al., 2001; Oki 
et al.,2004, 2005), with a shorter sphingosine, would selectively stimulate IL -4 
production from NKT cells, whereas aGalCer stimulation induces both IL -4 and 
IFN-?. Accordingly, OCH stimulation of NKT cells favors a Th2 bias of immune 
responses in vivo, as compared to aGalCer stimulation. a-linked sugars such as 
aGalCer are not recognized as a product of mammalian cells, implying that 
aGalCer is not a physiological ligand for NKT cells. Currently, it is well 
recognized that NKT cells can be activated during infectious diseases (Tupin et 
al., 2007). Interestingly, it has been reported that aGalCer-like glycosphingolipids 
are rather ubiquitously found in the environment, indicating that aGalCer may be 
actually derived from bacteria residing with the marine sponge. 
Other analogs of aGalCer have been shown to have various effects on NKT cell 
activation in vitro , as well as antimicrobial and antitumor activity in vivo. For 
example, modifying the acyl chain of the aGalCer molecule KRN7000 to create a 
diunsaturated 20 carbon chain results in IL -4 production with a reduction in IFN? 
secretion (Yu et al., 2005). In contrast to the effects of acyl chain modification on 
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aGalCer activity, Gonzalez-Aseguinolaza and colleagues used a different 
approach. In their studies, they used a C-glycosidic form of aGalCer in analyses 
of the adjuvant properties of aGalCer. It was found that the C-glycoside (a-C-
GalCer) induced more of a Th1 response, was longer lasting, and was actually a 
better adjuvant than the parental compound itself in murine models of malaria 
and metastatic melanoma (Gonzalez-Aseguinolaza et al., 2000 and 2002; 
Schmieg et al., 2003 and 2005; Yang et al., 2004). 
Ortaldo et al (Ortaldo et al., 2004), as well as Parekh et al (Parekh et al., 2004), 
have found that a 12 carbon acyl chain form of galactosylceramide (ßGalCer 
(C12)) can stimulate NKT cells in a CD1d-dependent manner. The administration 
of the ßGalCer (C12) in vivo caused the apparent loss of NKT cells as found with 
aGalCer, but without cytokine expression or activation of NK cells. Tetramers 
loaded with ßGalCer (C12) could stain NKT cells, although lower numbers were 
detected as compared with when aGalCer-loaded tetramers are used (Wilson et 
al., 2003; Crowe et al., 2003; Harada et al., 2004). However, some contamination 
with minute amounts of aGalCer cannot be completely ruled out in either of the 
ßGalCer preparations. Thus, ßGalCer may have some similar yet distinctly 
different actions on NKT cells. 
In 2005 three groups independently found that a predominant glycosphingolipid 
from the LPS-free Sphingomonas (S. capsulata, S. paucimobilis, and S. wittichii) 
and Ehrlichia muris bacteria could stimulate human and/or murine NKT cells in a 
CD1d-dependent manner (Kinjo et al., 2005 and 2006; Mattner et al., 2005; 
Sriram et al., 2005; Wu et al., 2005). All of these groups identified 
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aglucuronosylceramide (GSL-1) as this glycosphingolipid, with 
agalacturonosylceramide (GS-1`) also able to activate NKT cells. An additional 
unique aspect of GSL-1 as opposed to aGalCer is the NKT cell populations 
identified by CD1d1 tetramers or dimers loaded with this glycolipid. 
Approximately one-half of those NKT cells that are aGalCer/CD1d1 tetramer 
positive are GSL-1/CD1d1 dimer (or tetramer) positive. Two other sources of 
microbial products have been shown to be able to activate NKT cells. The 
Schaible group reported that Phosphatidylinositol mannoside (PIM) could 
stimulate both human and murine NKT cells (Fischer et al., 2004). Additionally, 
PIM-loaded CD1d tetramers could stain both human (PBL) and mouse (liver) 
NKT cells, although the latter detected a substantially smaller population than 
CD1d tetramers loaded with aGalCer. Despite this interesting observation clearly 
identifying PIM as a CD1d ligand, how PIM actually participates in the immune 
response against mycobacteria is not yet clear. 
Search for an endogenous ligand of NKT cells has led to the identification of 
lysosomal glycosphingolipid isoglobotrihexosylceramide (iGb3), a ß-linked sugar 
capable of stimulating NKT cells as a potential endogenous ligand for mouse and 
human NKT cells (Mattner et al., 2005; Zhou et al.,2004). With regard to the role 
of iGb3 in adaptive immune responses, Mattner et al. reported that Gram-
negative, LPS positive Salmonella typhimurium activates NKTcells through the 
recognition of iGb3, presented by LPS-activated dendritic cells. 
However, very recent works have cast doubt on the meaning of the iGb3 
discovery (Porubsky et al., 2007; Speak et al., 2007). The study by Zhou et al. 
 13 
(2004) indicated that iGb3 presented by CD1d-expressing CD4+CD8+  
thymocytes should be involved in the thymic positive selection of NKT cells. 
Porubsky et al. has then generated iGb3 synthetase deficient mice and examined 
if NKT cells are really missing in the mice lacking expression of iGb3. They found 
that the number and function of NKT cells were as normal as those seen in wild-
type mice. Using highly sensitive HPLC assay, Speak et al. sought for the 
presence of iGb3 in various mouse and human tissues. The only tissue 
containing iGb3 was the dorsal root ganglion of mice. No iGb3 was detected in 
any human tissue (Porubsky et al., 2007; Speak et al., 2007). These new findings 
do not support the idea that iGb3 is central in the selection of NKT cells and re-
opened the search for endogenous ligands for NKT cells.  
Two more natural lipid components of the cell membrane, the disialoganglioside 
(GD3) and Phosphatidylinositol (PI), have been shown to be CD1d presented 
Ags capable of stimulating (at least some) NKT cells (Brutkiewicz, 2006). 
 
Functional subsets of NKT cells   
During their development in the thymus, conventional aßT-cells acquire the 
expression of either CD4 or CD8, MHC coreceptors that define functionally 
distinct MHC-restricted T-cell subsets. In response to antigen stimulation, 
CD4+T-cells differentiate into T helper, Th1 or Th2 cells. Th1 cells produce the 
signature cytokine interferon IFN?, whereas Th2 cells produce interleukin IL-4, 
IL-5, IL-13, and IL -10. Similarly, effector CD8+T cells can be classified as Tc1 or 
Tc2 cells, which produce type 1 or type 2 cytokines, respectively (Woodland & 
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Dutton, 2003).  
The Th1/Th2 paradigm has recently been reevaluated to include a third 
population of T helper cells, producing IL -17 and designated Th17. These pro-
inflammatory T cells have been mostly studied in the mouse. Th17 cells exhibit a 
cytokine profile distinct from Th1 and Th2 cells, producing cytokines, such as IL-
17 and IL -22, and express a characteristic transcription factor retinoic acid 
receptor (RAR)-related orphan receptor gamma t (ROR?t). The differentiation of 
Th17 cells requires the coordinate and specific action of the proinflammatory 
cytokine IL-6 and the immunosuppressive cytokine TGF-ß. In addition, the IL-12 
family member IL-23 is involved in the maintenance of these cells (Korn et al., 
2007). A pro-inflammatory role in autoimmune diseases has been reported for IL-
17; furthermore IL -17 has been shown to be important for host defense against 
pathogens such as Klebsiella pneumoniae and Bacteroides fragilis (Stockinger 
and Veldhoen, 2007). The detection of IL-17-producing T cells in humans with 
inflammatory diseases, such as multiple sclerosis (MS), contact dermatitis (CD), 
rheumatoid arthritis (RA), and Lyme arthritis (Steinman, 2007) suggests that in 
humans these cells have a proinflammatory role similar to that described in 
mouse models (Rautajoki et al., 2008). 
From this perspective, the cytokine profiles of T-lymphocytes are thought to 
reflect their functional activities. In Figure 1 a model of the differentiation of 
CD4+CD8+ T-cells and activation of NKT cells is depicted. 
NKT cells are different from functionally differentiated conventional a/ß TCR 
bearing T-cells in that they are autoreactive (i.e., they can recognize self-
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glycolipids) and produce both Th1 and Th2 cytokines, including IL -4, IL-10, and 
IFN?, upon stimulation with their ligands (Taniguchi et al., 2003).  
Two major subsets of NKT cells with distinct effector functions have been 
identified.  
Lee et al hypothesized that NKT cells could promote Th2 responses in some 
conditions and Th1 in others for the presence of different characteristics. They 
reported that CD4+ and CD4-CD8- NKT cell subsets represent functionally 
distinct lineages with marked differences in their profile of cytokine secretion and 
pattern of expression of chemokine receptors, integrins, and NK receptors. 
CD4+NKT cells were the exclusive producers of IL -4 and IL-13 upon primary 
stimulation, whereas CD4-CD8- NKT cells had a strict Th1 profile and 
prominently expressed several NK lineage receptors (Lee et al., 2002). 
Gumperz et al also reported different characteristics for 2 distinguished subsets 
of NKT cells. CD4- NKT cells selectively produced Th1 cytokines as IFN?, TNFa 
and expressed NKG2d; this subset up-regulated perforin after exposure to IL -2 or 
IL-12. In contrast, CD4+ NKT cells potently produced both Th1 and Th2 
cytokines, up -regulated perforin in response to stimulation by phorbol myristate 
acetate and ionomycin but not IL-2 or IL-12, and could be induced to express 
CD95L (Gumperz et al., 2002). 
In attempt to better understand the contribution of NKT-DC crosstalk governing 
the Th1/2 balance, Liu et al demonstrated that 2 major distinct subsets of NKT 
cells, CD4+ and CD4–CD8–, express functional CD40 ligand (CD40L), but they 
differentially regulate the DC function by reciprocal NKT-DC interactions, thereby 
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influencing the subsequent Th response. The CD4+ subset stimulated by a-
GalCer-loaded DC immediately produced massive amounts of IL -4 and IL-13, 
which together with IFN? enhanced CD40L-induced IL-12 production by DC. 
In contrast, the CD4–CD8– subset eliminated the DC by cytolysis and changed 
the living DC into a default subtype, in turn markedly down-regulating the levels 
of IL-12. Therefore, the DC stimulated by the CD4+ subset preferentially induced 
Th1 responses, whereas the DC reacted with the CD4–CD8– subset induced a 
shift toward Th2 responses (Liu et al., 2008). 
Although human NKT cell subsets with distinct effector functions have been 
identified, it is unclear whether the effector functions of these subsets are 
imprinted during development or can be selectively reprogrammed in the 
periphery. 
Eger et al demonstrated that NKT cells from neonates are phenotypically and 
functionally distinct from adult NKT cell subsets (Eger et al., 2006). In 
comparison to adult CD4+ NKT cells, neonatal CD4+ NKT cells exhibit higher 
expression of the differentiation markers CCR7 and CD62L, lower expression of 
the NK cell markers CD161 and CD94, and are more amenable to effector 
function reprogramming. They also found wide heterogeneity within the adult 
CD4+ NKT cell subset for expression of memory markers, suggesting that the 
pool of CD4+ NKT cells in adult peripheral blood represents a more 
heterogeneous mixture of cells with respect to their phenotype and stage of 
maturation. They have hypothesized that adult NKT cells are not recent thymic 
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emigrants, but have undergone some form of peripheral maturation (Eger et al., 
2006). 
The invariant Va14+NKT cells (iVa14+NKT), also called type I NKT cells, include 
two defined populations: a CD4+ and a CD4-CD8- DN population; they express 
TCR repertoire consisting of Va14-Ja18 (in mice) or Va24-Ja18 (in humans). 
In addition to type I NKT cells, a population of CD1d-reactive NKT cells that 
express diverse non-Va14TCRs, referred to as type II NKT cells or noninvariant, 
has been described. These cells were identified based on the fact that NKT cell 
function was still detectable in mice lacking type I NKT cells but not in mice 
lacking CD1d (Godfrey et al., 2004). Although type II NKT cells are also restricted 
by CD1d, they do not recognize aGalCer. It is important to note, however, that 
some type II NKT cells are also autoreactive, as they recognize the endogenous 
myelin-derived glycolipid sulfatide and help protect mice against the development 
of experimental autoimmune encephalitis (Jahng et al., 2004).  
Type III or CD1d-independent NKT cells express a diverse repertoire restricted to 
classical MHC class I and II molecules, but not CD1d molecule. They are 
classified by surface expression of Ly49 or NK1.1 (CD161 in humans) and CD3. 
(Meyer et al., 2007). However some authors consider these cells as not 
belonging to NKT cells family and classify them as NKT-like cells (Godfrey et al., 
2004). Thus, different types of NKT cells appear to have distinct functional 
capabilities, but these functional differences have not been well characterized 
yet. Type I iVa14+NKT cells (referred to hereafter as NKT cells) have been 
shown to mediate both protective and regulatory immune functions. These 
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include tumor rejection, protection against infectious microbes, maintenance of 
transplant tolerance, and inhibition of autoimmune disease development 
(Taniguchi et al., 2003). However, it remains unclear whether distinct subsets or 
subtypes of CD1d-reactive NKT cells mediate different functions.  
Two new studies, suggest that a distinct subset of NKT cell mediates tumor 
rejection (Crowe et al., 2005), and that type II NKT cells suppress antitumor 
immunosurveillance (Terabe, 2005). These new studies might help explain the 
seemingly contradictory functions that have been ascribed to CD1d-reactive NKT 
cells. They also raise new questions about how subsets of NKT cells acquire 
distinct functional capabilities (Seino & Taniguchi, 2005). 
When activated, NKT cells respond with vigorous cytokine production within 1–2 
hours of TCR ligation (Godfrey and Hammond, 2000; Kronenberg and Gapin, 
2002). These cells release Th1-type cytokines including IFN? and TNFa, as well 
as Th2-type cytokines including IL -4 and IL-13 (Smyth and Godfrey, 2000; 
Wilson and Delovitch, 2003), and at least in mice, they seem to store or pre-form 
some mRNA for these cytokines even before activation with exogenous antigens 
(Matsuda et al., 2003 ; Stetson et al., 2003). Moreover, individual NKT cells are 
able to make both Th1- and Th2-type cytokines simultaneously following 
stimulation in vivo (Matsuda et al., 2000, 2003; Crowe et al., 2003), an unusual 
characteristic that at face value seems paradoxical, as Th1 cytokines often 
antagonize the action of Th2 cytokines and vice versa. Despite this Th0-like 
cytokine pattern, NKT cells can “go both ways,” as their activation in some cases 
can polarize the immune response in a Th1 direction, while in other cases a Th2 
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response is generated (Godfrey and Kronenberg, 2004). Adding to the 
unpredictability surrounding the functional consequences of NKT cell activation, 
these lymphocytes have been implicated as immunosuppressive cells in some 
systems, usually via their production of the Th2-type cytokines or IL-10, while in 
other systems, they appear to promote enhanced cell-mediated immunity via 
production of Th1-type cytokines (Smyth and Godfrey, 2000; Wilson and 
Delovitch, 2003). The mechanisms that determine the cytokine polarity of the 
NKT cell response, and the influence of the NKT cells response on the systemic 
immune system, are not well understood, and indeed, this problem represents a 
key challenge in the field of NKT cell research.  
In humans, during early phase of activation, NKT cells produce both Th1 and Th2 
cytokines; during later phases of activation, they predominantly produce 
proinflammatory cytokines such as IFN? and TNFa (Gumperz et al., 2002; Lee et 
al., 2002). Accordingly, the CD4+ cells are thought to be the major source of Th2 
cytokines for controlling Th1 cell-mediated inflammation or promoting Th2-
dependent pathologies. Although earlier studies have tended to focus on the 
ability of NKT cells to down-modulate inflammatory responses, more recent 
works have shown that they could promote joint inflammation in models of 
arthritis (Kim et al., 2005; Chiba et al., 2005; Ohnishi et al., 2005) or mediate 
airway inflammation in bronchial asthma (Akbari et al., 2003; Lisbonne et al., 
2003). The divergent effects of NKT cells in inflammatory pathologies are thought 
to reflect a broad spectrum of their functions in vivo. In fact, NKT cells explosively 
produce a number of pro- and anti-inflammatory cytokines after nonphysiological 
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stimulation with aGalCer or anti-CD3 mAb (Chen and Paul, 1997), although 
stimulation with alternative ligands such as aGalCer analogues may lead to 
selective Th1 (Schmieg et al., 2003) or Th2 cytokine production (Miyamoto et al., 
2001; Miyake and Yamamura, 2005).  
NKT cells usually exhibit only a marginal response in response to endogenous 
ligand bound with CD1d. However, when cytokines are added exogenously, the 
cells that recognize the endogenous ligand would produce a large amount of 
selected cytokines. For example, IL -12 induces production of IFN? (Brigl et al., 
2003), whereas IL -2 provokes IL-5 and IL-13 (Sakuishi et al., 2007). 
IL-12 induced production of IFN? (Brigl et al., 2003; Mattner et al., 2005) as well 
as IL-2 induced production of IL -5 (Sakuishi et al., 2007) depends upon the 
recognition of endogenous ligand via TCR. However, NKT cells could also 
produce a large amount of cytokines in response to cytokine signals 
independently of TCR signals. It has been shown that NKT cells can be activated 
by Escherichia coli LPS (via Toll Like Receptor 4), and produce IFN?, but not IL-
4. Nagarajan and Kronenberg have shown that the production of IFN? was 
dependent upon LPS-induced IL -12 and IL-18 from APC, but did not require 
CD1d-mediated presentation of an endogenous Ag. Furthermore, they showed 
that exposure to a combination of IL-12 and IL-18 sufficiently activated the 
NKTcells (Nagarajan and Kronenberg, 2007). TCR-independent production of 
Th1 cytokine strongly indicates the innate NK property of NKT cells. 
Beaudoin et al have recently shown that without applying any exogenous 
glycolipids, NKT cells could prevent a T cell-transfer model of diabetes by 
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inducing an anergic state of the pathogenic, islet-specific T cells. In contrast to 
other related works, this suppression did not require Th2 cytokines but was 
dependent upon direct cell-cell contact (Beaudoin et al., 2002). Subsequent 
studies showed that the cellular interaction does not involve CD1d recognition by 
NKT cells (Kent et al., 2005; Novak et al., 2007). The mechanism of NKT cell 
mediated regulation remains unclear, although a newly recognized NKT cells 
(MR1-restricted Va19 NKT cells) have been reported mediating immune 
regulation via direct contact with B cells independently from TCR recognition 
(Croxford et al., 2006). 
While NKT cells can also exhibit cytotoxic activity similar to CD8+ T cells, it is still 
unclear whether all NKT cells have this capability (Kawano et al., 1998). 
At least one study in humans demonstrated that the NKT cell pool can be divided 
into cytotoxic and noncytotoxic subsets, although all NKT cell subsets examined 
thus far constitutively express FasL and have the potential for cytotoxic activity 
via Fas (Ho et al., 2004). Interestingly, again in humans, a subset of cells that 
appears to be responsible for cytotoxic activity lacks CD4 expression, express 
CD8aa homodimers, are CD1d reactive and express the Va24 T-cell receptor 
(Ho et al., 2004).  
Antigen presentation and activation of NKT cells by non-professional APCs 
Stimulating NKT cells with aGalCer presented by professional APCs leads to 
production of both pro- and anti-inflammatory cytokines. However, when non-
professional APCs such as Schwann cells (Im et al., 2006) are used, aGalCer 
could induce a preferential production of Th2 cytokines from NKT cells.  
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Gober et al studied antigen presentation by CD1d-bearing KCs as well as CD1d 
bonemarrow-derived cells. NKT cells incubated with KCs and aGalCer did not 
secrete either IFN? or IL -4 as measured by a sensitive ELISA. In contrast, THP-
1, a monocyte-derived cell line, triggered robust IFN? secretion as well as 
significant IL-4 secretion. To confirm the ELISA data, in parallel, they extracted 
total cellular RNA from NKT cells and assayed IFN? and IL-4 gene expression 
using real-time PCR. The PCR data confirmed that NKT cells were triggered to 
activate IFN? and IL-4 gene expression in the presence of CD1d+ monocyte cell 
line and aGalCer, but not by CD1d-bearing KCs (Gober et al., 2007). Bonish et al 
studied the relative induction of IFN? and IL -4 production of three different NKT 
cells clones combined with either untreated or IFN? pretreated and extensively 
washed KCs in the presence of the lipid 12-O-tetradecanoyl phorbol-13-acetate 
(TPA). They reported that when untreated KCs were combined with these NK-T 
cell clones, virtually no IFN? was produced, but when KCs were pretreated with 
IFN?, the NK-T cell clones were stimulated to secrete IFN?. In contrast, the 
production of IL-4 was relatively low and was not consistently enhanced by 
combining any of the NK-T cell clones with either untreated or IFN? pretreated 
KCs. They therefore postulate that a positive feedback loop could be established 
in skin due to the presence of NK-T cells being activated to produce IFN? upon 
contact with CD1d-positive KCs, leading to further CD1d expression and 
subsequent NK-T cell release of more IFN? (Bonish et al., 2000). 
 
NKT and cytotoxicity  
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Previous investigations have focused on the activation and proliferation of NKT 
cells and shown this to be dependent on Va24 TCR recognition of a-GalCer and 
similar glycolipids presented by CD1d on antigen-presenting cells. The effector 
phase and functions of the DN NKT cells require further clari fication. Nicol et al 
described that one effector function of human DN NKT cells is cytotoxicity and 
that some human tumours are susceptible to this cytotoxic activity. This implies 
that activation of cytotoxic activities of DN NKT cells may be partly or wholly 
responsible for the anti-tumour effects of a-GalCer in humans. 
CD1d expression increased sensitivity to cytotoxic activity of DN NKT cells. All 
normal and tumour cells expressing CD1d including normal cells (DC and Mo-
DC), tumour cell lines and CD1dtransfected cells were susceptible to DN NKT 
cell cytotoxicity, with the exception of the Daudi cell line. The Daudi cell line 
expresses a b2-microglobulin-free form of CD1d and this could explain why they 
are not sensitive to killing. Monocytes, which do not express CD1d, were not 
susceptible to DN NKT cell cytotoxicity until CD1d expression was induced with 
differentiation into the Mo-DC phenotype by GM-CSF and IL -4. 
Cell lines were only susceptible to cytotoxicity after induction of CD1d expression 
by transfection and the resulting cytotoxic killing was inhibited by antibodies 
against CD1d. The a-GalCer further increased CD1d-mediated killing but 
cytotoxic activity resulting from CD1d expression on the target cells, without 
added a-GalCer implies the presence of a natural ligand present in the culture 
systems. An explanation is that Va24TCRs recognize CD1d without glycolipid 
presentation but that the affinity of CD1d ±TCR interaction is increased by the  
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glycolipid a-GalCer. Perforin (prf) appears to be a major component required for 
the induction of CD1d-independent cell lysis by DN NKT cells. This is indicated 
by the 80% inhibition of lytic activity resulting from the use of CMA which inhibits 
perforin-mediated killing. The finding that DN NKT cells have cytoplasmic perforin 
strengthens the case for a role for prf (Nicol et al., 2000). Killer lymphocytes 
release prf and granzymes from cytotoxic granules into the immunological 
synapse to destroy target cells as a critical mechanism in the defense against 
viruses and cancer. 
Prf, a Ca2+-dependent pore-forming protein that multimerizes in membranes, 
delivers granzymes into the target cell cytosol 
Once released from the cytotoxic lymphocytes , granzyme B (grzB) binds its 
receptor, the mannose-6-phosphate/insulin-like growth factor II receptor, and is 
endocytosed but remains arrested in endocytic vesicles until released by 
perforin. Once in the cytosol, grzB targets caspase-3 directly or indirectly through 
the mitochondria, initiating the caspase cascade to DNA fragmentation and 
apoptosis. Granzyme A (grzA), a serine protease in the cytotoxic granules of 
natural killer cells and cytotoxic T lymphocytes, induces caspase-independent 
cell death when introduced into target cells by prf. GrzA induces single -stranded 
DNA damage as well as rapid loss of cell membrane integrity and mitochondrial 
transmembrane potential through unknown mechanisms. 
GrzA is the most abundant protease in the cytotoxic granules of NK cells and 
cytotoxic T lymphocytes. Similar to grzB and prf, grzA is stored in cytotoxic 
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granules, which are specialized secretory lysosomes, and is released into the 
immunological synapse upon triggering by engagement with a target cell. 
GrzA and GrzB have been extensively studied, little is known about granzyme K. 
Flow cytometric analysis of peripheral blood lymphocytes revealed that grzA, 
grzM and prf show a similar distribution. They are expressed in almost all 
CD16CD56 NK cells, CD3CD56 NKT cells and CD T cells as well  as in 20–30% 
of all CD3CD8 TC cells. Surprisingly, grzK was not detected in the highly 
cytotoxic CD16CD56 NK cells, but was preferentially expressed in lymphocytes 
of the T cell lineage, staining 20% of CD3CD8 TC cells, 50% of CD3CD56 NKT 
cells and 40% of CDT cells, as well as 60% of the small sub-population of 
CD56bright NK cells suggesting that human granzymes are differentially 
expressed in distinct sub -populations of peripheral blood lymphocytes. 
Cell death induced by grzK involves the late release of DNA from target cells in a 
fashion similar to grzA. This is accompanied by a loss of the mitochondrial 
transmembrane potential and the generation of reactive oxygen species but does 
not involve caspase activation or chromatin condensation. 
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Table 1. Comparison between NKT cells, NK cells, T cells and CD25+CD4+ 
Tregs. 
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Figure 1 . Differentiation of CD4+CD8+ T-cells and activation of NKT cells. 
CD4+CD8+ T-cells can differentiate in CD4+, CD8+ and NKT cells (that can be 
double negative for CD4/CD8 or may be single positive for CD4 or CD8). CD4+ 
T-cells differentiate in Th1, Th2, Th17 and Treg. Each type of these cells is 
required for a specific immune response. NKT cells are stimulated by APC via 
CD1d-TCRaß interaction and rapidly produce Th1 or Th2 cytokines. They also 
have cytotoxicity activity through TRAIL, FasL and prf/Gr. 
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Materials and Methods 
Human subjects 
The criteria for enrollment of subjects in this study was the presence of a 1–2+ 
score of the patch test allergic reaction at 48 or 96 hours clinical readings 
(Belsito, 2004). Informed consent was obtained, and skin biopsy specimens were 
obtained from paired clinically normal skin and the patch test reaction sites. This 
study was approved by the University of Maryland Baltimore Institutional review 
board, and adhered to the Declaration of Helsinki Principles. The patients, 
allergens, patch test scoring, timing of obtaining the skin biopsy specimens from 
the patch test skin reactions are summarized in Table 2. One patient with plaque-
type psoriasis was studied as a disease control. A skin biopsy specimen was 
taken from uninvolved, clinically normal skin as well as the edge of a psoriatic 
plaque. 
 
RNA extraction, cDNA synthesis, and real -time PCR (RNeasy Mini Protocol, 
Qiagen, Valencia, CA) 
Skin biopsy specimens from paired clinically normal skin and elicitation sites of 
ACD were snap-frozen in liquid nitrogen and stored at -70°C until RNA 
extraction. RNA was extracted and cDNA was prepared, using previously 
published methods (Fishelevich et al., 2006). Real-time PCR (LightCycler, 
Roche, Indianapolis, IN) was used to confirm differences in the levels of 
expression of selected mRNA. The primers, PCR protocol, and product 
quantification for 18S ribosomal RNA were exactly as reported previously 
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(SYBER green detection) (Schmittgen and Zakrajsek, 2000). All other primers 
were designed and prepared by TIB Molbiol (Adelphia, NJ). Amplification (40–50 
cycles) of a single PCR product was confirmed by gel electrophoresis and 
melting curve analyses. The cDNAs were assayed in duplicate, and mean±SD 
values are depicted in the graphics for the quantitative PCR. 
PCR Detection of Perforin and granzymes mRNA was performed using RT-PCR. 
Sequences of the  primers were as follows:  
· prf  -sense, 5'GCCTCGGTGAAGAGAGGATA3'  
  -antisense, 5'AGCAGCAGGAGAAGGATGC3'  
· grzA -sense, 5'CAGTTGTCGTTTCTCTCCTGC3'  
  –antisense, 5'GGACCATGTAGGGTCTTGAA3'  
· grzB  –sense, 5'AACCAATCCTGCTTCTGCTG3'  
  –antisense, 5'AGATAAGCCATGTAGGGGCG3'  
· grzK  –sense, 5'CGTTTGTGGAGGTGTTCTGA3'  
  –antisense, 5'GAGAGTGTGCGCCTAAAACC3' 
The PCR products were run on an agarose gel and photographed.  
 
Reagents and antibodies 
Anti-prf, anti -grzA, anti-grzB mouse monoclonal antibodies and anti-grzK rabbit 
polyclonal Ab were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA); Anti-TCR Va24 and anti-Vb11 mAbs were from Immunotech (Fullerton, CA); 
goat anti-mouse IgG1 and IgG2a biotinylated antibodies, were purchased from 
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BD Pharmingen (San Diego, CA). Calcein-AM was purchased from Molecular 
Probes (Eugene, Oreg.) as a 1-mg/ml solution in dry dimethyl sulfoxide. 
 
Immunohistochemical procedures  
Frozen ACD samples were cut into 5-mm sections and fixed with cold acetone 
for 10 minutes. Perforin, Granzymes A and B were stained with mouse 
monoclonal antibody, whereas Granzyme K with rabbit polyclonal antibody by 
indirect immunofluorescence for frozen sections, followed by rhodamine or FITC 
conjugated secondary antibodies. NKT cells were detected for expression of both 
Va24 (IgG1) and Vb11 (IgG2a) using rhodamineconjugated goat anti-mouse IgG 
and goat-anti-mouse IgG subclass antibodies and streptavidin–FITC. For double 
immunofluorescence of NKT cells, frozen sections were stained with primary 
antibody to TCR Va24 or Vb11 by indirect immunofluorescence, followed by 
treatment with anti-prf/grzA/grzB/grzK Abs. The staining was observed with 
Nikon Eclipse E600 epifluorescence microscope equipped with a digital camera. 
The images were documented using SpotTM imaging system (Diagnostic 
Instruments, Sterling Heights, MI). 
 
Primary KC, HaCaT, THP-1 and K562 cell lines 
Single-cell suspension of KCs for primary culture was prepared by trypsinization 
of the epidermal sheets after separation from the dermis by dispase digestion of 
newborn foreskins, with approval of the local institutional review board. KCs were 
cultured in the 
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presence of low concentration of CaCl2 (0.05mM) in Epi-Life growth medium 
supplemented with epidermal growth factor and pituitary extracts (Cascade 
Biologics, Portland, OR) at 37°C with 5% CO2 in air. The human KC cell line 
HaCaT was cultured in DMEM with 10% fetal calf serum and antibiotics. THP-1 
and K562 cell lines were cultured in RPMI with 10% fetal calf serum and 
antibiotics. 
 
NKT-cell assay 
A highly enriched cell line (>98% Va24 positive) was developed using previously 
published methods (Motsinger et al., 2002). 
Cultured KCs were derived from foreskins and cultured in serumfree medium 
containing low (0.05mM) or high (1.20mM) CaCl2. KC culture was performed as 
published previously (Fishelevich et al., 2006). Twenty-four hours before co-
culture with NKT cells, the KC monolayers were treated with IFN-g (500U ml-1) to 
increase CD1d cell-surface expression. The KCs were trypsinized into single-cell 
suspensions and co-cultured with NKT cells in a 96-well, round-bottomed plate in 
a 5% CO2 atmosphere at 37°C for 24 hours in RPMI 1,640 with 10% fetal calf 
serum. After 24 hours, RNA was extracted to evaluate gene expression of prf 
and grzs (Pickering et al., 2002). Alpha-galactosylceramide was incubated with 
NKT cells for 15 minutes at 37°C. 
 
Cytotoxic assays 
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Cytotoxicity assays were performed according to the Calcein-release method, as 
previously described (Neri et al., 2001). 
After trypsinization, target cells (HaCat and primary KC) were resuspended in 
complete medium at a final concentration of 106/ml and incubated with 15 µM 
calcein-AM for 30 min at 37°C with occasional shaking. Afterwards they were  
plated at 5000 cells/well by using 96-well V-bottomed microtiter plates. 
The effector (NKT cells) was adjusted to a 10, 20, 30, 40:1 E/T ratio and applied 
in triplicate. After 4 hours of culture, plates were spun, and 100 mL of 
supernatant was removed from each well for calcein release measurement.  
Samples were measured using a Spectramax Gemini dual-scanning microplate 
spectrofluorimeter (Molecular Devices, Sunnyvale, Calif.) (excitation filter: 485± 9 
nm; band-pass filter: 530±9 nm). 
The percentage of specific lysis was calculated as 100 X (experimental release – 
spontaneous release)/(maximum release – spontaneous release). 
 
Statistical analyses 
Quantitative data were analyzed for statistically significant differences between 
control and treatment groups using the GraphPad Instat Software Program 
(GraphPad Software, San Diego, CA). Because multiple comparisons were 
examined, a one -way ANOVA (Tukey Kramer multiple analyses) or unpaired 
Students’ t-test for a simple analysis of two means were applied to the 
quantitative data (P<0.05 were considered significant). 
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Patient# Age/race/gender Allergen/scoring/duration 
 
CD#1 36yrs/white/male Gold/2+/96hrs 
 
CD#2 49yrs/black/female  Paraphenylendiamine/2+/48hrs 
 
CD#3 40yrs/white/male Balsam of Peru/1+/48hrs 
 
CD#4 53yrs/white/male Epoxy resin/1+/48hrs 
 
CD#5 71yrs/white/female  Nickel sulphate/2+/96hrs 
 
CD#6 26yrs/black/male Bacitracin/2+/48hrs 
 
CD#7 42yrs/white/male methylmethoxylate/1+/72 hrs 
 
 
Table 2. Patients’ characteristics, allergens, patch test scoring and timing of 
obtaining the skin biopsy specimens.  
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Results 
Cytotoxic molecules gene expression in ACD 
All the cytotoxic molecules were overexpressed in positive patche test reaction 
respect to normal skin. The fold-change increase is expressed as mean. GrzA 
increase was of 3.97 (p<0.01), whereas prf and grzB were respectively 4.29 and 
9.16 (p<0.05). A tendency to overexpression was also registered for grzK (2.04), 
even if there was no statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
4
8
12
16
Pe
rfo
rin
 **
Gr
an
z A
 *
Gr
an
z B
 **
Gr
an
z K
Fo
ld
-C
ha
ng
e 
in
 G
en
e 
E
xp
re
ss
io
n 
 
Nickel
PPD
Gold
Bacitracin
Epoxy
MMA
Balsam
Mean
 * P < 0.05
** P < 0.01
 35 
Co-localization of NKT cells and cytotoxic molecules in ACD. 
All the cytotoxic molecules were present in positive patch test reaction and co-
localized with NKT cells.  
 
 
 
 
 
 
        GrzB                                 Va24                                Merged 
GrzA                                  Vb11                               Merged 
GrzK                                   Va24                             Merged 
         PRF                                Vb11                        Merged 
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Gene expression during antigen presentation 
Granzymes were overexpressed during antigen presentation by THP-1 cells, 
especially when alpha-galactosylceramide was added. 
An increase of 4.40 was detected for grzA in the co-culture of NKT and THP-1 
cells, whereas an increase of 19.80 was registered when alpha-
galactosylceramide was added. There was an increase also for GrzB expression 
in the co-culture system (1.21), but with the adding of alpha-galactosylceramide it 
was of 3.99. We found a light increase of the expression of grzK (1.56) in the 
presence of alpha-galactosylceramide, but no increase in the co-culture system 
without the stimulus. No increase was registered for prf expression in both 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Granzymes A and B were overexpressed during antigen presentation by primary 
keratinocytes. An increase of 2.78 was detected for grzA in the co-culture of NKT 
cells and KCs, whereas an increase of 4.14 was registered when alpha-
galactosylceramide was added. There was an increase also for GrzB expression 
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in the co-culture system (2.92), but with the adding of alpha-galactosylceramide it 
was of 2.62; in this case there was no difference in adding the stimulus. No 
increase was detected for prf and grzK expression in both conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
NKT cell cyototoxic activity vs keratinocytes 
Cytotoxic activity of NKT cells is increased versus HaCat cells . The percentage 
of lysis was almost 50%, whereas the adding of alpha-galactosylceramide 
enabled NKT cells  to kill 100% of HaCat cells. 
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Similar results were registered when the same experiment was repeated with 
primary KCs. Furthermore in this case the effector : target ratio needed to reach 
these results was the half. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
The skin represents a unique immunologic organ poised to protect the host from 
invading organisms and environmental antigens. The skin is also an important 
target for a variety of allergic and autoimmune responses.  
NKT cells have been reported to play an active role in skin diseases such as 
contact sensitivity, have been implicated in atopic dermatitis, UV-induced 
immunosuppression and are present in psoriasis skin lesions.   
Delayed-type hypersensitivity in the form of contact hypersensitivity (CHS) to 
haptens is a clinically important syndrome known as allergic contact dermatitis 
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(ACD) (Belsito, 1999). ACD is an important dermatologic disease with 
considerable morbidity and economic impact; CD from both irritant and allergic 
sources comprise 6% to 10% of all dermatology clinic visits (Thyssen et al., 
2007). Some studies have focused on the role of NKT cells in CHS in 
experimental mouse models (Askenase, 2001; Campos et al., 2003; Stein-
Streilein, 2003; Nieuwenhuis et al., 2005). 
Campos et al indicated a role for this cell type in the early molecular events of 
CHS, in which NKT cells respond to hapten application and interact with B-1 
lymphocytes, resulting in production of hapten-specific IgM (Campos et al., 2003) 
These findings were confirmed by an in vitro system too (Campos et al., 2006). 
Askenase et al. assessed that elicitation of CHS begins with an initiation process 
that results in T-cell recruitment. In fact, there are two starting points, both 
involving cells of the innate immune system. The first of these is induction of the 
initiation process. The other is actual initiation of the late elicited effector phase 
due to recruitment of the T-cells. Induction of the initiating process, which 
subsequently elicits T-cell recruitment, begins within minutes of immunization by 
postulated release of endogenous glycolipids from the sensitizing site. These 
glycolipids bind to CD1d on APCs, leading to the activation of NKTcells; these 
release IL -4 to coactivate B-1 cells.  
In the second of the two mentioned starting points, initiation of the effector phase 
occurs within minutes of secondary local Ag challenge, when B-1 cell derived 
IgM antibodies trigger an elicitation cascade of innate responses. This starts with 
classical complement activation, generating C5a, which in turn activates mast 
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cells and platelets to release TNFa and serotonin; these then activate endothelial 
cells, leading to local T-cell recruitment (Askenase et al., 2004). Gober et al 
reported that CD1d gene expression was increased in elicitation sites of ACD 
relative to normal human skin. Similarly, both CD161 gene expression and 
variable region of TCR Va24, JaQ region of TCR gene expression in skin lesions 
of ACD were increased relative to normal skin, indicating that invariant NKT cells 
are commonly present in the T-lymphocyte infiltrate of ACD. It was demonstrated 
that human invariant NKT cells regularly appear in the lymphocytic infiltrate that 
occurs during the elicitation phase of human ACD, either at the 48 or 96 hours 
time frame of clinical readings of this skin reaction by immunohistochemistry, 
real-time PCR, as well as nested PCR (Gober et al., 2007). Lee et al. reported 
that in healthy adults, NKT cells are present at a very low frequency in the 
peripheral blood, approximately 0.1% of the total population of peripheral blood 
leukocytes (Lee et al., 2002). Based on this they demonstrated the frequency of 
NKT cells in the ACD lesions to range from 1.72 to as high as 33% of the total 
CD2+ infiltrating T lymphocytes, this representing a relative enrichment of NKT 
cells ranging from a 17- to 330-fold enrichment above the normally very low 
frequency found in the peripheral blood. This suggests that NKT cells may be 
specifically recruited into ACD sites, rather than a passive extravasation event, in 
which relative enrichment of frequency relative to other cell types would be 
expected not to occur. Additionally, immunohistochemical studies of ACD 
demonstrated that there was abundant KC apoptosis in this condition as well as 
atopic dermatitis, suggesting cell mediated cytotoxicity is active in both condtions 
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(Trautman et al., 2001). Our results show that cytotoxic molecules expression is 
increased in ACD and that cytotoxic molecules are co-localized with NKT cells in 
ACD. Furthermore prf and granzymes expression is increased during the process 
of antigen presentation; The increase is higher when THP-1 are the APC cells, 
especially when aGalCer is added. Also KC are able to behave as APC cells to 
NKT cells, especially when they are treated with IFN? and aGalCer. Another 
finding is represented by the cytotoxic activity of NKT cells versus keratinocytes. 
NKT cells are able to kill keratinocytes and this killing is increased by aGalCer.   
From our data we can assess that NKT cells are in an activated state in the 
elicitation phase of ACD. The importance of NKT cells, at least, in the priming 
phase of CS is reinforced by numerous experiments, even if further work is 
needed to be performed to better understand the role of NKT cells in the 
elicitation phase too, and in ACD in general. 
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